AC Immune S.A.
ACIU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $27 | $15 | $4 | $0 |
| % Growth | 84.5% | 276.1% | – | – |
| Cost of Goods Sold | $63 | $55 | $0 | $0 |
| Gross Profit | -$35 | -$40 | $4 | $0 |
| % Margin | -129.1% | -268.9% | 100% | – |
| R&D Expenses | $63 | $55 | $60 | $62 |
| G&A Expenses | $11 | $11 | $10 | $11 |
| SG&A Expenses | $11 | $11 | $10 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$57 | -$51 | $5 | $6 |
| Operating Expenses | $17 | $14 | $75 | $79 |
| Operating Income | -$52 | -$54 | -$71 | -$79 |
| % Margin | -191.8% | -362.3% | -1,800.4% | – |
| Other Income/Exp. Net | $1 | -$1 | $0 | $6 |
| Pre-Tax Income | -$51 | -$54 | -$71 | -$73 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$51 | -$54 | -$71 | -$73 |
| % Margin | -186.4% | -366.4% | -1,798% | – |
| EPS | -0.51 | -0.64 | -0.85 | -0.97 |
| % Growth | 20.3% | 24.7% | 12.4% | – |
| EPS Diluted | -0.51 | -0.64 | -0.85 | -0.97 |
| Weighted Avg Shares Out | 100 | 85 | 84 | 75 |
| Weighted Avg Shares Out Dil | 100 | 85 | 84 | 75 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $1 | $0 | $6 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$49 | -$52 | -$68 | -$70 |
| % Margin | -178% | -350.2% | -1,728.7% | – |